Filed by newsfilecorp.com For Immediate Release ORGENESIS APPROVED FOR EURO 12.3 MILLION EUROPEAN GRANT FOR FURTHER DEVELOPMENT OF ITS TYPE 1

ORGENESIS APPROVED FOR EURO 12.3 MILLION EUROPEAN GRANT FOR

DEVELOPMENT OF ITS TYPE 1 DIABETES PROGRAM

GERMANTOWN, MD February 13, 2017 Orgenesis Inc. (OTCQB:

ORGS), a fully-integrated cell therapy and contract development and

manufacturing company, announced that its Belgian subsidiary, Orgenesis SPRL,

has received the formal approval from the Walloon Region, Belgium (Service

Public of Wallonia, DGO6) for a budget of 12.3 million ($12.8 million) support

program for the GMP production of AIP cells for two clinical trials that will be

performed in Germany and Belgium. The project support will be for a period of

three years commencing on January 1, 2017.

Of the approved amount, a total of 3.3 million is budgeted for

a development work at our Belgian-based subsidiary, MaSTherCell S.A.

We are thankful for the continuing support of from the Walloon

Region for our European activity, said Vered Caplan, CEO of Orgenesis. Through

our collaboration with Pall Corporation and MaSTherCell, our wholly-owned

contract manufacturer and development organization (CDMO), our activity in the

Walloon Region has been tremendously productive.

Orgenesis is pioneering work in developing technology to

successfully reprogram human liver cells into glucose-responsive, fully

functional Insulin Producing Cells (IPCs). The objective of the European program

is to further the development of a cGMP (Current Good Manufacturing Practice)

and implement its technology on a high-efficiency industrial scale. Converting a

diabetic patient's own liver cells into insulin-producing cells has the

potential to provide insulin independence for those suffering from Type 1

About DGO6 (Service Public of Wallonie)

DGO6 Economy Employment Research is a branch of the

Administration of Wallonia, Belgium. Through its Technology Development

Department, the Walloon Region has set up several attractive incentives to boost

regional innovation and research and to support companies, from start-ups to

well-established enterprises, in their way to innovation and successful

About Orgenesis Inc.

Orgenesis is a vertically-integrated biopharmaceutical company

with expertise and unique experience in cell therapy development and

manufacturing. In addition, through its Israeli subsidiary, Orgenesis Ltd.,

Orgenesis is a pioneer in the development of technology designed to successfully

reprogram human liver cells into glucose-responsive, fully functional, Insulin

Producing Cells (IPCs). Orgenesis believes that converting the diabetic

patient's own tissue into insulin-producing cells has the potential to overcome

the significant issues of donor shortage, cost and exposure to chronic

immunosuppressive therapy associated with islet cell transplantation. This

integrated approach supports Orgenesis's business philosophy of bringing to

market significant life-improving medical treatments. For more information,

visit www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements that

involve substantial uncertainties and risks. These forward-looking statements

are based upon our current expectations, estimates and projections and reflect

our beliefs and assumptions based upon information available to us at the date

of this release. We caution readers that forward-looking statements are

predictions based on our current expectations about future events. These

forward-looking statements are not guarantees of future performance and are

subject to risks, uncertainties and assumptions that are difficult to predict.

Our actual results, performance or achievements could differ materially from

those expressed or implied by the forward-looking statements as a result of a

number of factors, including, but not limited to, our ability to raise working

capital to support our business, the development of our regeneration technology

as therapeutic treatment for diabetes which could, if successful, be a cure for

Type 1 Diabetes; our limited financial resources and our ability to raise the

working capital needed to fund the commitments of our CDMO business, various

joint ventures, development projects and business generally; the successful

integration of our clinical and CDMO strategy; our technology not working as

well as expected; our ability to retain key employees; our ability to satisfy

the rigorous regulatory requirements for new medical procedures; our competitors

developing better or cheaper alternatives to our products and the risks and

uncertainties discussed under the heading "RISK FACTORS" in Item 1 of our Annual

Report on Form 10-K for the fiscal year ended November 30, 2015, and in our

other filings with the Securities and Exchange Commission. We undertake no

obligation to revise or update any forward-looking statement for any reason.